{"analyses":[{"ciLowerLimit":"0.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.45","estimateComment":"Hazard ratio was estimated using weighted Cox proportional hazard model and confidence interval was estimated using robust error variance.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.21","statisticalMethod":"Weighted Cox proportional hazard model"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"11.99","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"4.99","upperLimit":"13.60","value":"7.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"DOR was defined as the time from the first documentation of OR, until confirmed disease progression (PD) per IMWG criteria, or death due to any cause, whichever occurred first. PD= increase of \\>=25% from lowest value in \\>=1 of following (serum M-protein \\[absolute increase \\>=0.5g/dL\\]; serum M-protein increase \\>=1g/dL \\[when lowest M-protein \\>=5g/dL\\]; and urine M-protein \\[absolute increase \\>=200mg/24h\\]). Median and 95% Confidence Interval (CI) reported in the descriptive section was determined using unweighted analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with TCR MM who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) were included.","id":"OG000","title":"Study C1071003 Cohort A"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from Flatiron Health database were included.","id":"OG001","title":"Flatiron Health Cohort"}],"paramType":"MEDIAN","populationDescription":"Eligible participants from study C1071003 (Cohort A) and RW participants identified from COTA and Flatiron Health databases were included. Here, \"Overall Number of Participants Analyzed\" is the number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first documentation of OR until confirmed PD or death due to any cause or censoring date (median follow-up of 10.4 months for study C1071003 cohort A, 8.8 months and 7.7 months for COTA and Flatiron Health cohorts)","title":"Duration of Response-Comparison Between Elranatamab in Study C1071003 Cohort A and Flatiron Health Cohort Using IPTW Analysis","type":"SECONDARY","unitOfMeasure":"Months"}